Riskpilot← Back to searchSign inGet full accessgenebeats AB
ABActiveOrg 5592892516Ekvägen 4Engineering activities and related technical consultancy · NACE 7112Est. 20200 employees
Revenue 2025
SEK 0
EBITDA margin
—
+56% vs 2024
Equity ratio
92.0%
Financial strength
Net profit 2025
SEK 381K
+659% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -114K | +56% |
| Net profit | SEK 381K | +659% |
| Total assets | SEK 1,7M | -16% |
| Equity | SEK 1,5M | +12% |
| Employees | 0 | — |
Legal name
genebeats AB
Org number
5592892516
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
10 december 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Emirandetti Reinius, Björn Lennart
Company purpose
Bolaget ämnar bedriva verksamhet inom medicinteknisk verksamhet, tillverkning och konsultation samt därmed förenlig verksamhet.
Address
Ekvägen 4
Email
bjorn.reinius@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 395 | 768 | 165 | 0 | 0 |
| Staff expenses | — | −8 | −0 | −158 | −0 |
| EBITDA | 2 880 | 620 | 37 | −257 | −114 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 2 880 | 620 | 37 | −257 | −114 |
| Net financials | −27 | −217 | 91 | 92 | 75 |
| Profit before tax | 2 133 | 403 | 128 | 48 | 469 |
| Tax | −462 | −129 | — | 2 | −88 |
| Net profit | 1 671 | 274 | 128 | 50 | 381 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 735 | 3 111 | 2 415 | 2 002 | 1 676 |
| Equity | 1 696 | 1 599 | 1 526 | 1 372 | 1 543 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 1 319 | 792 | 169 | 122 | 133 |
| Total debt | 1 319 | 792 | 169 | 122 | 133 |
EBITDA margin
-11356800.0%
This company
15.8%
Market median
-71878581% vs market
20212025
Equity ratio
92.0%
This company
38.2%
Market median
+141% vs market
20212025
Return on equity
24.7%
This company
18.4%
Market median
+34% vs market
20212025
Net profit margin
38084300.0%
This company
8.1%
Market median
+470176443% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AE Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of genebeats AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Amanda Emirandetti | Deputy Chief Executive Officer | 0 companies |
| Björn Lennart Reinius | Chairman | 0 companies |
| Per David Wickman | Deputy Board Member | 0 companies |